Vericel Corporation VCEL 深 沪
等待开盘 04-01 09:30:00 美东时间
32.17
+1.620
+5.30%
华盛通- 最 高32.30
- 今 开31.27
- 成交量 95.13万股
- 最 低 31.06
- 昨 收 30.55
- 总市值 16.33亿
- 52周最高 45.97
- 市盈率 静 101.58
- 换手率 1.87%
- 52周最低 28.95
- 委 比 -2.52%
- 总股本 5076.33万
- 历史最高 68.94
- 量 比 0.95
- 振 幅 4.06%
- 历史最低 1.11
- 每 手 1
- 风险率 3.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多新浪财经ESG：Vericel Corporation MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:34
Vericel Corporation Announces Virtual Annual Shareholder Meeting
Vericel Corporation Announces Virtual Annual Shareholder Meeting Vericel will hold a virtual annual meeting of shareholders on April 29, 2026, via live audio webcast. Shareholders will vote on the election of seven directors to serve one-year terms expiring at the 2027 annual meeting. An advisory vo
03-19 19:32
FDA approves Vericel’s Burlington facility for MACI commercial manufacturing
FDA approves Vericel’s Burlington facility for MACI commercial manufacturing Vericel Corporation said the U.S. Food and Drug Administration approved commercial manufacturing of MACI (autologous cultured chondrocytes on porcine collagen membrane) at the company’s new cell therapy manufacturing facili
03-04 21:06
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
Vericel Corporation received FDA approval to begin commercial production of MACI in its new Burlington facility, supporting capacity expansion and potential international commercialization.
03-04 13:00
Vericel to Present at Multiple Upcoming Investor Conferences
Vericel Corporation will present at TD Cowen's 46th Annual Healthcare Conference on March 4, 2026, and at Leerink Partners' 2026 Global Healthcare Conference on March 10, 2026. The presentations will be available online. Vericel, a leader in advanced therapies for sports medicine and severe burn care, markets three products: MACI® for knee cartilage repair, Epicel® for severe burns, and NexoBrid® for eschar removal.
03-03 13:30
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $64
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $60 to $64.
02-28 00:11
财报速睇 | Vericel Corporation 2025财年年度营收2.76亿美元，同比增长16.5%；归母净利润0.17亿美元，同比增长59.4%
华盛资讯2月26日讯，Vericel Corporation公布2025财年年度业绩，公司年度营收2.76亿美元，同比增长16.5%，归母净利润0.17亿美元，同比增长59.4%。
02-26 22:21
财报速睇 | Vericel Corporation 2025财年Q4营收0.93亿美元，同比增长23.3%；归母净利润0.23亿美元，同比增长17.3%
华盛资讯2月26日讯，Vericel Corporation公布2025财年Q4业绩，公司Q4营收0.93亿美元，同比增长23.3%，归母净利润0.23亿美元，同比增长17.3%。
02-26 21:19
Vericel Sees FY2026 Sales $316.000M-$326.000M vs $325.310M Est
2026 Financial GuidanceTotal revenue of $316 to $326 millionMACI revenue of $280 to $286 millionGross margin of approximately 75%Adjusted EBITDA margin of approximately 27%
02-26 21:04
